These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 34599031)

  • 1. Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence.
    Slingluff CL; Lewis KD; Andtbacka R; Hyngstrom J; Milhem M; Markovic SN; Bowles T; Hamid O; Hernandez-Aya L; Claveau J; Jang S; Philips P; Holtan SG; Shaheen MF; Curti B; Schmidt W; Butler MO; Paramo J; Lutzky J; Padmanabhan A; Thomas S; Milton D; Pecora A; Sato T; Hsueh E; Badarinath S; Keech J; Kalmadi S; Kumar P; Weber R; Levine E; Berger A; Bar A; Beck JT; Travers JB; Mihalcioiu C; Gastman B; Beitsch P; Rapisuwon S; Glaspy J; McCarron EC; Gupta V; Behl D; Blumenstein B; Peterkin JJ
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial.
    Eggermont AMM; Kicinski M; Blank CU; Mandala M; Long GV; Atkinson V; Dalle S; Haydon A; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Koornstra R; Hernandez-Aya L; Di Giacomo AM; van den Eertwegh AJM; Grob JJ; Gutzmer R; Jamal R; Lorigan PC; Krepler C; Ibrahim N; Marreaud S; van Akkooi A; Robert C; Suciu S
    JAMA Oncol; 2020 Apr; 6(4):519-527. PubMed ID: 31895407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF
    Dummer R; Brase JC; Garrett J; Campbell CD; Gasal E; Squires M; Gusenleitner D; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Flaherty K; Larkin J; Robert C; Kefford R; Kirkwood JM; Hauschild A; Schadendorf D; Long GV
    Lancet Oncol; 2020 Mar; 21(3):358-372. PubMed ID: 32007138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant vemurafenib in resected, BRAF
    Maio M; Lewis K; Demidov L; Mandalà M; Bondarenko I; Ascierto PA; Herbert C; Mackiewicz A; Rutkowski P; Guminski A; Goodman GR; Simmons B; Ye C; Yan Y; Schadendorf D;
    Lancet Oncol; 2018 Apr; 19(4):510-520. PubMed ID: 29477665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma.
    Eggermont AMM; Blank CU; Mandala M; Long GV; Atkinson VG; Dalle S; Haydon A; Lichinitser M; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Koornstra R; Hernandez-Aya L; Di Giacomo AM; van den Eertwegh AJ; Grob JJ; Gutzmer R; Jamal R; Lorigan PC; Lupinacci R; Krepler C; Ibrahim N; Kicinski M; Marreaud S; van Akkooi AC; Suciu S; Robert C
    Eur J Cancer; 2019 Jul; 116():148-157. PubMed ID: 31200321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial.
    Eggermont AMM; Blank CU; Mandalà M; Long GV; Atkinson VG; Dalle S; Haydon AM; Meshcheryakov A; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Koornstra R; Hernandez-Aya L; Di Giacomo AM; van den Eertwegh AJM; Grob JJ; Gutzmer R; Jamal R; Lorigan PC; van Akkooi ACJ; Krepler C; Ibrahim N; Marreaud S; Kicinski M; Suciu S; Robert C;
    Lancet Oncol; 2021 May; 22(5):643-654. PubMed ID: 33857412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases: a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial.
    Schimanski CC; Möhler M; Schön M; van Cutsem E; Greil R; Bechstein WO; Hegewisch-Becker S; von Wichert G; Vöhringer M; Heike M; Heinemann V; Peeters M; Kanzler S; Kasper S; Overkamp F; Schröder J; Seehofer D; Kullmann F; Linz B; Schmidtmann I; Smith-Machnow V; Gockel I; Lang H; Galle PR
    BMC Cancer; 2012 Apr; 12():144. PubMed ID: 22494623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.
    Eggermont AM; Chiarion-Sileni V; Grob JJ; Dummer R; Wolchok JD; Schmidt H; Hamid O; Robert C; Ascierto PA; Richards JM; Lebbé C; Ferraresi V; Smylie M; Weber JS; Maio M; Konto C; Hoos A; de Pril V; Gurunath RK; de Schaetzen G; Suciu S; Testori A
    Lancet Oncol; 2015 May; 16(5):522-30. PubMed ID: 25840693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multi-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high-risk melanoma patients: A subgroup analysis.
    Chick RC; Faries MB; Hale DF; Kemp Bohan PM; Hickerson AT; Vreeland TJ; Myers JW; Cindass JL; Brown TA; Hyngstrom J; Berger AC; Jakub JW; Sussman JJ; Shaheen M; Clifton GT; Park H; Sloan AJ; Wagner T; Peoples GE
    Cancer Med; 2021 Jul; 10(13):4302-4311. PubMed ID: 33982452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial.
    Ascierto PA; Del Vecchio M; Mandalá M; Gogas H; Arance AM; Dalle S; Cowey CL; Schenker M; Grob JJ; Chiarion-Sileni V; Márquez-Rodas I; Butler MO; Maio M; Middleton MR; de la Cruz-Merino L; Arenberger P; Atkinson V; Hill A; Fecher LA; Millward M; Khushalani NI; Queirolo P; Lobo M; de Pril V; Loffredo J; Larkin J; Weber J
    Lancet Oncol; 2020 Nov; 21(11):1465-1477. PubMed ID: 32961119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase IIb Randomized Controlled Trial of the TLPLDC Vaccine as Adjuvant Therapy After Surgical Resection of Stage III/IV Melanoma: A Primary Analysis.
    Vreeland TJ; Clifton GT; Hale DF; Chick RC; Hickerson AT; Cindass JL; Adams AM; Bohan PMK; Andtbacka RHI; Berger AC; Jakub JW; Sussman JJ; Terando AM; Wagner T; Peoples GE; Faries MB
    Ann Surg Oncol; 2021 Oct; 28(11):6126-6137. PubMed ID: 33641012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial.
    Eggermont AMM; Blank CU; Mandala M; Long GV; Atkinson VG; Dalle S; Haydon AM; Meshcheryakov A; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Koornstra R; Hernandez-Aya L; Di Giacomo AM; van den Eertwegh AJM; Grob JJ; Gutzmer R; Jamal R; Lorigan PC; van Akkooi ACJ; Krepler C; Ibrahim N; Marreaud S; Kicinski M; Suciu S; Robert C
    J Clin Oncol; 2020 Nov; 38(33):3925-3936. PubMed ID: 32946353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine.
    Bystryn JC; Zeleniuch-Jacquotte A; Oratz R; Shapiro RL; Harris MN; Roses DF
    Clin Cancer Res; 2001 Jul; 7(7):1882-7. PubMed ID: 11448900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial.
    Livingstone E; Zimmer L; Hassel JC; Fluck M; Eigentler TK; Loquai C; Haferkamp S; Gutzmer R; Meier F; Mohr P; Hauschild A; Schilling B; Menzer C; Kiecker F; Dippel E; Roesch A; Ziemer M; Conrad B; Körner S; Windemuth-Kieselbach C; Schwarz L; Garbe C; Becker JC; Schadendorf D;
    Lancet; 2022 Oct; 400(10358):1117-1129. PubMed ID: 36099927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial.
    Schadendorf D; Luke JJ; Ascierto PA; Long GV; Rutkowski P; Khattak A; Del Vecchio M; de la Cruz-Merino L; Mackiewicz J; Sileni VC; Kirkwood JM; Robert C; Grob JJ; Dummer R; Carlino MS; Zhao Y; Kalabis M; Krepler C; Eggermont A; Scolyer RA
    J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38485189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma.
    Weber JS; Ascierto PA; Middleton MR; Hennicken D; Zoffoli R; Pieters A; Amadi A; Kupas K; Kotapati S; Moshyk A; Schadendorf D
    Eur J Cancer; 2021 Nov; 158():225-233. PubMed ID: 34663559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study.
    Corrie PG; Marshall A; Dunn JA; Middleton MR; Nathan PD; Gore M; Davidson N; Nicholson S; Kelly CG; Marples M; Danson SJ; Marshall E; Houston SJ; Board RE; Waterston AM; Nobes JP; Harries M; Kumar S; Young G; Lorigan P
    Lancet Oncol; 2014 May; 15(6):620-30. PubMed ID: 24745696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial.
    Wallack MK; Sivanandham M; Balch CM; Urist MM; Bland KI; Murray D; Robinson WA; Flaherty L; Richards JM; Bartolucci AA; Rosen L
    J Am Coll Surg; 1998 Jul; 187(1):69-77; discussion 77-9. PubMed ID: 9660028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.
    Bottomley A; Coens C; Mierzynska J; Blank CU; Mandalà M; Long GV; Atkinson VG; Dalle S; Haydon AM; Meshcheryakov A; Khattak A; Carlino MS; Sandhu S; Puig S; Ascierto PA; Larkin J; Lorigan PC; Rutkowski P; Schadendorf D; Koornstra R; Hernandez-Aya L; Di Giacomo AM; van den Eertwegh AJM; Grob JJ; Gutzmer R; Jamal R; van Akkooi ACJ; Krepler C; Ibrahim N; Marreaud S; Kicinski M; Suciu S; Robert C; Eggermont AMM;
    Lancet Oncol; 2021 May; 22(5):655-664. PubMed ID: 33857414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Dreno B; Thompson JF; Smithers BM; Santinami M; Jouary T; Gutzmer R; Levchenko E; Rutkowski P; Grob JJ; Korovin S; Drucis K; Grange F; Machet L; Hersey P; Krajsova I; Testori A; Conry R; Guillot B; Kruit WHJ; Demidov L; Thompson JA; Bondarenko I; Jaroszek J; Puig S; Cinat G; Hauschild A; Goeman JJ; van Houwelingen HC; Ulloa-Montoya F; Callegaro A; Dizier B; Spiessens B; Debois M; Brichard VG; Louahed J; Therasse P; Debruyne C; Kirkwood JM
    Lancet Oncol; 2018 Jul; 19(7):916-929. PubMed ID: 29908991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.